Our Strategy

Medizone International, Inc. Corporate Strategy

Medizone  International  (OTCBB: MZEI) has completed its initial product development stage through its development partner, ADA, and is in the process of rolling out early-adopter production units of its disinfection technology, AsepticSure™.

The primary focus continues to be in the field of hospital sterilization, although a multitude of peripheral markets has been determined over the past two years. These additional markets include: food processing, clean rooms, hospitality and tourism, airlines, cruise ships, bed bugs and bio-terrorism countermeasures.

This primary hospital and healthcare development pathway was initially based, in part, on a review of published data on hospital-derived infections, an area of rapidly growing concern in the medical community and subject to increasing governmental oversight and regulation on both a state and federal level in the United States and extensive scrutiny in Canada, the UK and Europe.

Today, having not only successfully completed phase one hospital beta testing, but also having had AsepticSure's efficacy officially peer reviewed and subsequently published in the American Journal Of Infection Control, Medizone International is poised to enter the hospital and healthcare markets early in 2012.

Medizone's extensive experience with ozone technologies and its bio-oxidative qualities has contributed greatly in pursuing this initiative. Near term efforts have been directed toward one of the Company's founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing virtually all biological fluids  which includes blood, serum, and plasma and its fractionates, as well as all biologically contaminated equipment and spaces.

Medizone is discovering that its unique ozone generating technologies when combined with other new emerging technologies will play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as "The Silent Epidemic" silent epidemic: CA-MRSA and HA-MRSA,Richard P. Evans, MD, American Academy of Orthopedic Surgeons, May 2008,  “AAOS Study”, in reference to MRSA (methicillin-resistant staphylococcus aureus) infection.

Additional Hospital Beta Testing

The Company is currently preparing for full-scale hospital trials, both in Canada and the US. These are anticipated to begin in the second half of 2012.

Initial Sales of AsepticSure™

Commencement of commercial deliveries is anticipated early in 2012
Medizone's target is to achieve profitability moving into early 2013

Partnership with Multinational Corporation

Medizone International expects to partner with a large corporation embedded in the hospital  sector for increased:

Manufacturing Capacity
Sales
Service